View in EDS

Mezigdomide combined with bortezomib disrupts the cell cycle and elicits superior antitumor effects in multiple myeloma.

Saved in:
Bibliographic Details
Title: Mezigdomide combined with bortezomib disrupts the cell cycle and elicits superior antitumor effects in multiple myeloma.
Authors: Bjorklund CC; Bristol Myers Squibb, Translational Development, Summit, NJ., Larrayoz M; Center for Applied Medical Research CIMA, Cancer Center University of Navarra, Navarra Institute for Health Research (IDISNA), Centro de Investigation Biomedica en Red (CIBERONC), Pamplona, Spain., Kang J; Bristol Myers Squibb, Translational Development, Summit, NJ., Chiu H; Bristol Myers Squibb, Translational Development, Summit, NJ., Shtraizent N; Bristol Myers Squibb, Translational Development, Summit, NJ., Wu L; Bristol Myers Squibb, Translational Development, Summit, NJ., Li S; Bristol Myers Squibb, Translational Development, Summit, NJ., Hsu CC; Bristol Myers Squibb, Translational Development, Summit, NJ., Zhao J; Bristol Myers Squibb, Translational Development, Summit, NJ., Amatangelo M; Bristol Myers Squibb, Translational Development, Summit, NJ., Chow TT; Bristol Myers Squibb, Translational Development, Summit, NJ., Wollerman K; Bristol Myers Squibb, Translational Development, Summit, NJ., Singh RK; Biocon Bristol Myers Squibb, Research and Development Centre, Syngene International Ltd, Bangalore, India., Sridhara S; Biocon Bristol Myers Squibb, Research and Development Centre, Syngene International Ltd, Bangalore, India., Dudhgaonkar S; Bristol Myers Squibb, Research and Development, Bangalore, India., Subramanyam P; Biocon Bristol Myers Squibb, Research and Development Centre, Syngene International Ltd, Bangalore, India., Ghosh K; Bristol Myers Squibb, Research and Development, Bangalore, India., Richardson PG; Dana-Farber Cancer Institute, Jerome Lipper Multiple Myeloma Center, Boston, MA., Bahlis NJ; Arnie Charbonneau Cancer Institute, Cumming School of Medicine, Department of Oncology, University of Calgary, Calgary, AB, Canada., Thakurta A; Bristol Myers Squibb, Translational Development, Summit, NJ.; Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom., Martinez-Climent JA; Center for Applied Medical Research CIMA, Cancer Center University of Navarra, Navarra Institute for Health Research (IDISNA), Centro de Investigation Biomedica en Red (CIBERONC), Pamplona, Spain., Gandhi AK; Bristol Myers Squibb, Translational Development, Summit, NJ., Hagner PR; Bristol Myers Squibb, Translational Development, Summit, NJ.
Source: Blood neoplasia [Blood Neoplasia] 2025 Nov 07; Vol. 3 (1), pp. 100179. Date of Electronic Publication: 2025 Nov 07 (Print Publication: 2026).
Publication Type: Journal Article
Journal Info: Publisher: Elsevier, Inc Country of Publication: United States NLM ID: 9918841988906676 Publication Model: eCollection Cited Medium: Internet ISSN: 2950-3280 (Electronic) Linking ISSN: 29503280 NLM ISO Abbreviation: Blood Neoplasia Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2950-3280
DOI:10.1016/j.bneo.2025.100179